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Abstract Matrix metalloproteinases (MMPs) are involved in 
physiological tissue remodeling and pathological conditions like 
tumour metastasis and joint destruction. Until now, no con- 
venient and sensitive MMP-activity assay in crude media like 
synodal fluid has been available. Therefore, the highly soluble 
fluorogenic substrate TNO211 (Dabcyl-Gaba-Pro-Gin-Gly-Leu- 
GIu(EDANS)-AIa-Lys-NH2), containing the MMP cleavable 
Gly-Leu bond and EDANS/Dabcyl as fluorophore/quencer 
combination, was synthesized and characterized as an MMP 
specific substrate. We show that the fluorogenic assay using 
] NO211 is sensitive and can detect MMP activity in culture 
medium from endothelial cells and untreated synovial fluid (SF) 
from RA and OA patients, and control subjects. MMP activity 
in SF significantly increased in the order C < OA < RA, thus the 
frequent use of OA samples as control in studies on RA is 
debatable. 
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1. Introduction 
than 5% of total MMP), net enzyme activity is more appro- 
priate than total amounts of (pro)MMPs plus MMP-TIMP 
complexes as frequently determined by immunoassay [4-7]. 
Activity assays from MMPs comprise methods based on phy- 
siological substrates (e.g. radiolabeled collagen, casein or pro- 
teoglycans) or synthetic substrates. The former methods are 
mostly too insensitive for detection of MMP activity in un- 
activated biological media. Recently, the use of fluorogenic 
peptides for measuring activity of purified MMPs was de- 
scribed [8-11]. These substrates consist of a fluorophore and 
a light-absorbing group (quencher) attached to an amino acid 
sequence that is recognized by MMPs. After enzymatic leav- 
age the quenching is eliminated and fluorescence is observed. 
So far, the use of this kind of substrates in synthetic MMP- 
inhibitor studies or biological media is hampered by optical 
disturbances from the medium and their low solubility, due to 
the (lipophilic) fluorophores and quenchers used. 
The present study was designed to develop a water soluble 
fluorogenic MMP substrate containing the charged EDANS/ 
Dabcyl group [12] and apply it to relatively complex samples 
such as cell culture medium and synovial fluid. 
Matrix metalloproteinases (MMPs; e.g. collagenases, tro- 
melysins and gelatinases) are involved in the degradation of 
I le extracellular matrix in physiological nd pathophysiologi- 
c tl turnover of tissues. In particular, elevated levels of MMPs 
have been found in pathological conditions uch as rheuma- 
tfid arthritis, osteoarthritis [1], and tumour metastasis [2,3]. 
After excretion from the cell as inactive pro-enzyme 
(~roMMPs), MMPs undergo extracellular activation into the 
active enzyme, which can be rapidly neutralized by reversible, 
s oichiometric binding with tissue inhibitors of metallopro- 
t;inases (TIMPs). Therefore, to assess the potential of matrix 
cegradation by MMPs (levels of active MMP are usually less 
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.bbreviations: APMA, 4-aminophenylmercuric acetate; Cha, cyclo- 
]:exylalanine; Cys(Me), S-methylcysteine; Dabcyl, 4-(4-methylamino- 
Fhenylazo)benzoyl; Dnp, 2,4-dinitrophenyl; Dpa, N-3-(2,4- 
dinitrophenyl)-L-2,3-diaminopropionyl; EDANS, 5-((2-aminoethyl) 
amino)naphthalene-l-sulphonic acid; KIU, kallikrein inhibitor units; 
Mca, (7-methoxycoumarin-4-yl)acetyl; MMP, matrix metalloprotein- 
ase; Nma, N-methylanthranilic a id; RP-HPLC, reversed-phase high- 
performance liquid chromatography; RS-47,112, [4-(N-hydroxyami- 
n o)-2R-isobutyl-3S-(thiopen-2-ylthiomethyl)succinyl]-L-phenylalanine- 
N-methylamide; TFA, trifluoroacetic acid; TOF-MALDI, time-of- 
flight matrix-assisted laser desorption-ionisation; u-PA, urokinase- 
type plasminogen activator. 
2. Materials and methods 
2.1. Synthesis of fluorogenic substrate TN0211 
The fluorogenic substrate Dabcyl-Gaba-Pro-Gln-Gly-Leu-Glu 
(EDANS)-AIa-Lys-NH2 was synthesized according to the method e- 
scribed by Drijfhout et al. [13]. 
2.2. Proteolytic enzymes 
The gelatinase zymogens pro-MMP-2 [14] (EC 3.4.24.24) and pro- 
MMP-9 [15] (EC 3.4.24.35) were kindly provided by Dr. H. Nagase 
(University of Kansas, USA) and Dr. V. Kn~.uper (Strangeways Lab- 
oratories, Cambridge, UK), respectively. Recombinant human stro- 
melysin [11] (active form, MMP-3; EC 3.4.24.17) and the 19 kDa 
catalytic domain of collagenase [16,17] (19 kDa MMP-1; EC 
3.4.24.7) were a gift from Dr. J. McGeehan (Glaxo Inc., Research 
Triangle Park, NC, USA). The 19 kDa MMP-1 has the same specific 
activity for small peptide substrate as full length MMP-I [17,18] and 
was therefore considered suitable for the present study. Pro-MMP-2 
was activated at 37°C for 2 h and pro-MMP-9 at 4°C for 18 h in 
buffer A (50 mM Tris (pH 7.6), 150 mM NaC1, 5 mM CaC12, 1 gM 
ZnC12, 0.01% Brij 35) plus 1 mM APMA, resulting in > 90% activa- 
tion into the active enzymes (validated with gelatin zymography [19]). 
Plasmin (EC 3.4.21.7) was obtained from Kordia (Leiden, the Nether- 
lands), human recombinant urokinase-type lasminogen activator (u- 
PA, EC 3.4.21.73), from Serono (Aubonne, Switzerland) and human 
neutrophil elastase (EC 3.4.21.37) from the Bloodbank (Leiden, the 
Netherlands); all these enzymes were supplied in the active form. 
2.3. Incubation conditions 
All incubations were performed at 37°C in buffer A, unless stated 
otherwise. Enzyme and substrate were preincubated separately for 
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5 min at 37°C. lnhibitors NazEDTA and aprotinin (Kordia, Leiden, 
The Netherlands) were dissolved in buffer A. A stock solution (10 
mM) of the MMP inhibitor RS-47,112 (gift of Dr. R. Martin, Roche 
Bioscience, Palo Alto, CA, USA; also known as BB-94 [20]) was 
made in DMSO. Conversion of TNO211 by plasmin, u-PA, or elas- 
tase was investigated by incubation of 5 ~tM substrate with high con- 
centrations of these enzymes (100 nM) in buffer A by monitoring 
fluorescence (Xex =340 nm, ~%r~ =485 nm; Kontron SFM-25 fluori- 
meter). 
2.4. Solubility of fluorogenic substrates 
Saturated solutions of 50 nmol peptide in 100 I.tl incubation buffer 
A were made without the addition of organic solvents. After 1 h at 
37°C and 5 min of vortexing, the samples were centrifuged (5 min at 
10000×g) to remove insoluble material, and were subjected to RP- 
HPLC to determine the solubility of the substrate. Mca-Pro-Leu-Gly- 
Leu-Dpa-Ala-Arg-NH2 was from Bachem (Bubendorf, Switzerland) 
and DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(Nma)-NH2 was a gift 
from Dr. J. McGeehan [11]. 
2.5. Reversed phase-high performance liquid chromatography 
(RP-HPLC) 
Purification of synthesized peptide and quantitation of cleavage 
products was determined with a Perkin-Elmer C18 Pecosphere 
3×3C column eluted with a linear acetonitrile gradient in 0.1% 
TFA; 1.0 ml/min delivered by a Gynkotek Model 480 pump. Samples 
were injected with a WISP model 710B automated injector (Waters); 
detection comprised absorbance at 214 or 520 nm (Applied Biosys- 
terns Model 759A) and a Jasco Model 821-FP fluorescence detector 
(L~x = 340 nm, ~m = 485 nm). Data analysis was performed with Peak- 
master v3.2 (Harley Systems, Bucks, UK). Identity of the substrate 
and cleavage products was established by TOF-MALDI mass spec- 
trometry [21] (Lasermat, Finnigan MAT) and amino acid analysis of 
collected fractions [22]. 
2.6. Enzyme kinetics 
Proteolytic enzymes (19 kDa MMP-1, 25nM; MMP-2, 1.5 nM; 
MMP-3, 7.2 nM; MMP-9, 1.5 nM) were incubated with 1.8 btM 
TNO211 in buffer A. At 0, 20, 40, 60 and 90 min, 50 I.tl aliquots 
were added to an equal volume of ice-cold 40 mM EDTA in 0.1% 
TFA. Substrate concentrations at time point zero, [S]0, and other time 
points, [S]t, were quantified by RP-HPLC. Catalytic efficiencies (kcat/ 
Km values) were calculated from the equation [S]d[S]0 = e -kt, with 
k = [E]tot'(kcatlK~n) [11,23]. 
2. 7. MMP activity in synovial fluid and culture medium 
The feasibility of applying EDANS/Dabcyl peptides to determine 
MMP activity was investigated with synovial fluid and tissue culture 
samples. Synovial fluids were obtained from patients with rheumatoid 
arthritis (RA-SF; n = 8, mean age 48 years, range 32-73 years), pa- 
tients with osteoarthritis (OA-SF; n= 5, mean 66 years, range 52 80 
years), and post mortem from individuals without any sign of arthri- 
tis, which were regarded as controls (C-SF; n = 9, mean 45 years, 23- 
76 years). After centrifugation (4°C, 10000×g, 15 min) and 5-fold 
dilution with incubation buffer A, MMP activity of 75 I.tl diluted 
SF (without activation of proMMPs) was measured at 37°C with 
substrate TNO211 (5 ~tM) in a total volume of 150 Ixl incubation 
buffer. Increase in fluorescence was followed continuously (X~x = 340 
nm, ~m=485 nm; Kontron SFM-25 fluorometer). Incubation time 
was extended up to 6 h for samples containing low activity to acquire 
reliable ARFU/time data. Conditioned media (75 IXl) from untreated 
human umbilical vein endothelial cells cultured under serum-free con- 
ditions for 24 h [19] were incubated with 5 ~tM TNO211 in a total 
volume of 150 lal. Increase in fluorescence was measured as mentioned 
above. To some incubations of biological media enzyme inhibitors 
were added (see figure legends for details). 
3. Results 
3.1. Substrate cleavage site 
Substrate TNO211 (Dabcyl-Gaba-Pro-Gln-Gly-Leu-Glu 
(EDANS)-Ala-Lys-NH2) was incubated with all MMPs  avail- 
able and hydrolysis was followed by RP-HPLC to confirm 
that cleavage occurred exclusively at the Gly-Leu bond: in- 
cubation of substrate TNO211 with MMP-9 results in two 
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Fig. 1. Cleavage of TNO211 by MMP-9. HPLC analysis of incubation mixtures of TNO211 in the absence or presence of MMP-9: S, the par- 
ent peptide Dabcyl-Gaba-Pro-Gln-Gly-Leu-Glu(EDANS)-Ala-Lys-NH2 (MH+me~ =1327.6, MH+coac =1326.5); NS, the N-terminal fragment 
(Dabcyl-Gaba-Pro-Gln-Gly; MH+m~ =638.3, MH+calc =637.3; CS, the C-terminal cleavage product (Leu-Glu(EDANS)-Ala-Lys-NHz). Note 
the quenched fluorescence of the parent peptide. Small differences in retention times correspond to void volumes between detectors. 
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I'ig. 2. Time and enzyme dependence of the turnover of TNO211. Change in fluorescence (ARFU) increased linearly with time upon incubation 
t,f TNO211 (5 gM) with MMP-1 (A, 50 nM; ©, 20 nM; A, 10 nM; O, 5 nM; v, 2.5 nM; I), 1 nM). No change in fluorescence was ob- 
.,erved with buffer only (l), or a high concentration f MMP-1 (50 nM) in the presence of 10 mM EDTA (0; coincides with the data of the 
,~abstrate control). The rate of change in fluorescence (ARFU/time) derived from the lines in (A) was proportional to the concentration f
"vIMP- 1 (B). 
~ew peaks (at 214 nm) in the chromatogram, with a conco- 
mitant decrease in peak height of the substrate peak (Fig. 1). 
~'he first peak also exhibited fluorescence. Using amino acid 
,malysis, this peak was identified as the C-terminal hydrolysis 
product Leu-Glu(EDANS)-Ala-Lys-NH2. Detection at 520 
nm (Dabcyl group) showed two major peaks in the chroma- 
togram: the parent compound (S) and the N-terminal cleav- 
~ge product Dabcyl-Gaba-Pro-Gln-Gly (NS). The identity of 
~he latter was confirmed by amino acid analysis and mass 
,pectrometry (MH+m~.~=638.3). This exclusive cleavage of 
~he Gly-Leu bond was found for all the MMPs tested. 
(2. Fluorescence response of EDANSlDabcyl peptides 
To establish whether measurement of fluorescence is a re- 
lection of turnover of the synthetic substrates, the fluores- 
,:ence was related to the amount of cleavage product formed 
measured by HPLC). Incubation of TNO211 with MMP-9 
&owed that fluorescence values are proportional to the 
amount of N-terminal cleavage product, Dabcyl-Gaba-Pro- 
Gln-Gly (r > 0.999) and EDANS fluorescence being quenched 
')8.4% by Dabcyl. Furthermore, the rate of increase in fluor- 
~zscence was linearly related to the amount of enzyme 
r>0.99; 5 gM TNO211, Fig. 2). TNO211 allows sensitive 
neasurement of MMP activity: for instance, 1 nM MMP-1 
"an routinely be measured in a 10 rain incubation with pur- 
fled enzyme (Fig. 2). Substantially lower detection limits 
down to 10 pM) can simply be achieved by increasing the 
ncubation time. 
t.3. Enzyme kinetic properties and solubility of 
EDANSIDabcyl peptides 
For all TNO211-MMP combinations tested, first order en- 
zyme kinetics were observed: incubations howed a linear 
decrease of ln([S]t/[S]0) as a function of time (r > 0.99). Cata- 
lytic efficiencies kc~tlKm, ranged from 21000 (MMP-1) to 
619000 M -1 s -1 (MMP-2, see Table 1). Fluorogenic sub- 
strates studied by others show large differences in k~tIKm 
values between the different MMPs [8,9]. For instance, two 
commercially available fluorogenic substrates, Mca-Pro-Leu- 
Gly-Leu-Dpa-Ala-Arg-NH2 [9] and DNP-Pro-Leu-Gly-Leu- 
Trp-Ala-D-Arg [8] show a 40-70-fold higher k~tIKm for 
MMP-2 (even at 25°C) than for MMP-1 (at 37°C; Table 1). 
For substrate TNO211, this ratio between MMP-2 and 
3O 
2O 
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0 2 ;  0 _ , , IAOIAOIA(  
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Fig. 3. Hydrolysis of EDANS/Dabcyl substrates by MMP-1, plas- 
min, u-PA, or elastase. TNO211 (5 p.M) was incubated at 37°C 
with 100 nM plasmin (l), u-PA (zx), or elastase (O). No change in 
fluorescence was observed. In contrast, a substantially ower concen- 
tration of MMP-1 (O, 1 nM) resulted in a rapid increase in fluores- 
cence. 
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Fig. 4. MMP enzyme activity in unactivated culture medium or synovial fluid. Unactivated culture medium (A) or synovial fluid (B) was incu- 
bated with substrate TNO211 (5 I.tM; 37°C). Conditioned medium from human umbilical vein endothelial cells (serum-free; 2-fold diluted, e) 
resulted in increasing fluorescence (ARFU), linearly with time. This increase in fluorescence was totally abolished by 10 mM EDTA (©, A). 
Fluorescence r sulting from the cleaved fluorogenic substrate increased linearly with time in the presence of synovial fluid from a rheumatoid 
arthritis patient (10-fold diluted, e). Addition of the synthetic MMP-inhibitor RS-47,112 (also known as BB-94; 10 ~tM) suppressed the change 
in fluorescence effectively (©, B). 
MMP-1 (both determined at 37°C) is only 29. The catalytic 
efficiency of TNO211 for MMP-3 is 2-fold greater than that 
for MMP-1, similar to Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg- 
NH2 (1.6-fold). Altogether, TNO211 represents a general 
MMP substrate. Furthermore, TNO211 was highly soluble 
(80 IxM) in buffer without the addition of organic solvents, 
in contrast o MMP substrates containing Mca/Dnp or Nma/ 
Dnp as fluorophore/quencher couple (less than 5 ~tM, Table 
1). In synthetic MMP-inhibitor studies where substrate con- 
centrations up to 3 times Km are preferable (estimated for 
TNO211, Km =25 ktM, and for Mca-Pro-Leu-Gly-Leu-Dpa- 
Ala-Arg-NH2, Km= 70 p.M, both for MMP-2 [9]), substrate 
TNO211 is favoured over the lipophilic substrates containing 
Mca/Dnp or Nma/Dnp. 
3.4. Specificity of EDANS/Dabcyl peptides for MMPs 
In biological fluids and culture media proteinases other 
than MMPs can be abundant like the serine proteinases plas- 
min and u-PA, and the metalloproteinase elastase [24,25]. 
Cleavage of the EDANS/Dabcyl substrates by these enzymes 
will interfere in an MMP-activity assay. Therefore, incuba- 
tions were performed with fluorogenic substrate TNO211 
and 100 nM plasmin, u-PA or elastase. The increase in flu©r- 
escence was followed in time and compared to the hydrolysis 
by 100-fold lower concentrations of MMP-1 (1 nM). No con- 
version of the substrate by plasmin, u-PA or elastase was 
detected after 30 min, whereas increase in fluorescence with 
as low as 1 nM MMP-1 could easily be monitored (Fig. 3). 
Furthermore, addition of 10 mM EDTA (Fig. 4) or 1,10- 
phenanthroline totally abolished the conversion of substrates. 
In conclusion, interference by elastase or serine proteinases in
MMP-activity assays in crude media with TNO211 is unlikely. 
3.5. MMP activity in culture medium and synovial fluid 
Although several fluorogenic substrates for MMPs have 
been described, their application to measure MMP activity 
in biological media has not yet been reported or failed [8] 
due to optical interactions of the fluorophore with the med- 
ium. Since the emission wavelength of EDANS is relatively 
high (485 nm) in comparison to other fluorophores used in 
fluorogenic MMP substrates, disturbances from the medium 
will be less severe. 
Serum-free medium from non-activated human endothelial 
cells have been shown to contain MMPs (predominantly ge- 
latinases [19]). When incubated with TNO211, a linear in- 
crease in fluorescence was observed within minutes, indicating 
Table 1 
MMP substrate: amino acid sequence, solubility and catalytic efficiency (kcat/Km) at 37°C 
Substrate Solubility a (~tM) kcJKm (× 103) (M -1 s -1) Ref. 
MMP-1 MMP-2 MMP-3 MMP-9 
TNO211 Dabcyl-Gaba-Pro-Gln-Gly • Leu-GIu(EDANS)-Ala-Lys-NH2 80 
Dnp-Pro-Leu-Gly • Leu-Trp°Ala-o-Arg-NH2 N.D. 
Mca-Pro-Leu-Gly • Leu-Dpa-Ala-Arg-NH2 4.3 
Dnp-Pro-Cha-Gly • Cys(Me)-His-Ala-Lys(Nma)-NH2 4.6 
21 619 40 206 
0.83 58 b 2.2 [8] 
14.8 629 b 23 [8] 
13 86.6 [11] 
v, MMP cleavage site; N.D. not determined. 
~Solubility in buffer A without addition of organic solvents; 
bDetermined at 25°C. 
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fig. 5. MMP enzyme activity in synovial fluid from controls, os- 
~,zoarthritis and rheumatoid arthritis patients. MMP activity in syno- 
", ial fluids measured with TNO211. Closed symbols are individual 
rata, open symbols represent the group mean+S.D. See Section 2 
9r incubation details. Student's t-test was used for statistical naly- 
' LS, 
I he presence of active MMPs in the conditioned medium. The 
~addition of EDTA totally suppressed the increase of fluores- 
,ence ( > 99%; Fig. 4A). Also, unactivated synovial fluid from 
heumatoid arthritis patients caused a linear increase in fiuor- 
~:scence with time (Fig. 4B). This increase in fluorescence 
,'ould be inhibited 94% by 10 gM RS-47,112 (a synthetic 
VIMP inhibitor [20]) or 10 mM EDTA (95% inhibition). As 
xpected, no inhibition was found when 10 I.tM (400 KIU/ml) 
~protinin, a serine proteinase inhibitor, was added to the in- 
.:ubation. These experiments indicate that only MMPs in SF 
tre responsible for the turnover of the fluorogenic substrate 
FNO211. Synovial fluids from patients with osteoarthritis and 
tom patients with rheumatoid arthritis showed significantly 
ligher MMP activities with TNO211 than control SF, indicat- 
ng increased levels of active MMPs in pathological situations 
Fig. 5). Although activities in control subjects were low, en- 
',ymatic activity could be reliably quantified by extending in- 
:ubation time up to 6 h. Since MMP activity was significantly 
ncreased in OA vs. control SF, the frequent use of osteoar- 
hritis patients as controls in studies with respect o MMPs on 
"heumatoid arthritis can be debated and merits further inves- 
igation. 
;. Discussion 
The present study shows that synthetic peptides with 
EDANS and Dabcyl groups are efficiently hydrolyzed by 
MMPs. TNO211 seems a good substrate in enzyme kinetic 
~tudies or inhibitor studies because of its high solubility. 
Furthermore, the fluorescence properties of the substrate al- 
low convenient measurement of MMP activity in complex 
biological media like synovial fluid and culture medium. Since 
active MMP is detected only, this type of assay will be more 
useful than immunological methods where antibodies also rec- 
ognize inhibited forms of MMP [4-7]. MMP activity in SF 
could be indicative for joint destruction and therefore used as 
a marker in prognostic, therapeutic or diagnostic studies. 
However, we realize that the fairly general substrate 
TNO211 is not ideal to gain insight in the role of specific 
MMPs in physiological and pathological types of tissue 
remodeling. Therefore, new EDANS/Dabcyl substrates selec- 
tive for classes of MMPs are presently under investigation. 
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